Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile
- 1 February 2018
- journal article
- letter
- Published by Elsevier in European Urology
- Vol. 73 (2) , 308-310
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyJournal of Clinical Oncology, 2017
- Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell CarcinomaEuropean Urology, 2017
- Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell CarcinomaEuropean Urology, 2017
- Systemic Therapy for Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2017
- Hypermutation In Pancreatic CancerGastroenterology, 2017
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNAPLOS ONE, 2015
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancerScience, 2015
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013
- Sunitinib rechallenge in metastatic renal cell carcinoma patientsCancer, 2010
- Role ofVHLGene Mutation in Human CancerJournal of Clinical Oncology, 2004